Iovance Biotherapeutics IOVA
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 2nd percentile, 5-year average -4.7x
Near the top of its 5-year range · 88th percentile, 5-year average 3.1x
#4258 of 5331 stocks by PB (1 = cheapest)
Around its usual level · 52nd percentile, 5-year average 657.7x
#4465 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 4.42 | – | 3.06 | 88% (pricier than usual) | #4258 of 5331 (1 = cheapest) |
| PE | -15.84 | -56.52 | -4.75 | 2% (cheaper than usual) | – |
| PS | 9.47 | 6.42 | 657.73 | 52% (pricier than usual) | #4465 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on IOVA.
Sign in to join the discussion.